<DOC>
	<DOCNO>NCT00080457</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Thelin™ ( sitaxsentan sodium ) compare placebo ( sugar pill ) treatment patient pulmonary arterial hypertension ( PAH ) .</brief_summary>
	<brief_title>Safety Efficacy Study Sitaxentan Sodium ( Thelin™ ) Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy Thelin™ ( sitaxsentan sodium ) compare placebo treatment patient PAH . A cohort patient randomize usual treatment Tracleer® ( bosentan ) observational comparison safety efficacy .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Have current diagnosis symptomatic PAH classify one following : 1. primary pulmonary hypertension ( PPH ) also know idiopathic pulmonary arterial hypertension ( IPAH ) ; 2 . PAH associate connective tissue disease ; 3 . PAH associate one follow congenital heart defect : 1. repair ASD , VSD PDA great one year postoperative 2. unrepaired secundum ASD ( rest oxygen saturation great 88 percent room air measure oximeter ) World Health Organization ( WHO ) functional class II , III , IV Greater 12 less 75 year age Women childbearing potential must use two form medically acceptable contraception ( least one barrier method ) Have cardiac catheterization within 6 month study entry show follow value : 1. mean pulmonary artery pressure ( PAPm ) great 25 mmHg ( rest ) , 2. pulmonary capillary wedge pressure ( PCWP ) leave ventricularend diastolic pressure le 15 mmHg , 3. pulmonary vascular resistance ( PVR ) great 3 mmHg/L/min . Portal hypertension chronic liver disease ALT AST level great 1.5 time upper limit normal Screening Visit Contraindication treatment endothelin receptor antagonist Recent history abuse alcohol illicit drug Chronic renal insufficiency Pregnant breastfeed Atrial septostomy within 30 day study entry Previous failure bosentan safety concern lack clinical response</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Primary secondary pulmonary arterial hypertension</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Connective tissue disease</keyword>
	<keyword>Congenital heart defect</keyword>
	<keyword>Lupus</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>